- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of December 4
The Center for Biosimilars recaps the top 5 articles for the week of December 4.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 4.
Number 5: The efficient use of modeling and simulation may allow for better decision making that can increase the likelihood of successful outcomes in biosimilar development.
Number 4: At the American Society of Hematology’s 59th Annual Meeting and Exposition in Atlanta, Georgia, a research team will present findings that community-based lymphoma care is associated with guideline-discordant use of rituximab.
Number 3: Rival insulin makers Novo Nordisk and Sanofi both announced positive data on their products that could help them to stave off biosimilar and follow-on competition.
Number 2: Research shows that savings generated from the use of biosimilar filgrastim can expand access to high-cost drugs.
Number 1: A new report from the National Academy of Sciences, Engineering, and Medicine calls for big changes in how US pharmaceuticals are priced, promoted, and sold, so that treatments are more affordable and equally available to all Americans.
Finally, last week, our e-newsletter asked whether you think prescribers, patients, or payers are the key drivers of biosimilar uptake. To see results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
